| Date | Title | | | 02/02/12 | StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial| NEWARK, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD), the most common form of AMD. AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million peopl... |
|  | | 01/30/12 | StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision| NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of preclinical data demonstrating that its proprietary HuCNS-SC® cells (purified human neural stem cells) protect host photoreceptors and preserve vision in an animal model of retinal disease. The preclinical results are highly relevant to human disorders of vision loss, the most notable of which is dry age-related macular degeneration (AMD). The study is available online at http:... |
| | | 01/09/12 | StemCells, Inc. to Present at Biotech Showcase 2012| NEWARK, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that Martin McGlynn, President and CEO, will present a business update at the Biotech Showcase 2012 to be held January 9-11 at the Parc 55 Wyndham Hotel in San Francisco, California. Mr. McGlynn is scheduled to speak on Tuesday, January 10, at 1:45 ... |
| |
|
